lilly glp 1 agonist Eli to seek approval of new GLP-1 weight-loss drug this year LLY -0.60% today as Lilly's
Description
CagriSema produced ~22.7% weight loss (vs
Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation
Additionally, growing health awareness across age groups is boosting demand for medically supervised weight loss solutions, further supporting market expansion
Medicare coverage for the drugs would total about $35 billion from 2026 to 2034 , per a Congressional Budget Office (CBO) analysis in October 2024
